["{\n\"step_by_step_thinking\": \"There is no mention of ivosidenib in the provided documents. The documents discuss Interleukin 2 (IL2) for acute leukemia, obtaining drugs from foreign markets, legal implications of using drugs and devices in dental offices, where transformation occurs in acute leukemia, and new chemotherapy agents for the 1990s. Since ivosidenib is not mentioned, we cannot determine if it has been FDA-approved for use against acute myeloid leukemia.\",\n\"answer_choice\": \"B: no\"\n}"]